Jeet Mahal was named Principal Financial Officer of Jasper Therapeutics, Inc. As of November 6, 2026, Jasper Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 21, 2026 to September 28, 2026, naming 2 appointments and 1 departure (Form 8-K, September 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Jasper Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Jeet Mahal · Role: Principal Financial Officer · 8-K, 2026-09-28
- · In / out: In · Person: Patrick Crutcher · Role: Director · 8-K, 2026-07-17
- · In / out: Out · Person: Christian Nolet · 8-K, 2026-05-21
Jasper Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-21 to 2026-09-28. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Jasper Therapeutics, Inc. files it.
Also on the record for Jasper Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 6.4% of the class | 5%+ stakes | Source |
| August 17, 2026 | Stake report, Schedule 13G, by Velan Capital Investment Management LP | 9.9% of the class | 5%+ stakes | Source |
| August 5, 2026 | Form D, private offering | $132M sold | Form D page | Source |
| July 20, 2026 | Stake report, Schedule 13D/A, by Velan Capital Investment Management LP | 9.88% of the class | 5%+ stakes | Source |
| July 16, 2026 | Acquired Kira Pharmaceuticals | $132M | Acquisition | Source |
| July 10, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 1.7% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 4.8% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Management, L.P. | 1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 0.5% of the class | 5%+ stakes | Source |
| February 25, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.8% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13D/A, by The Carlyle Group Inc. | 3.8% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by THE GOLDMAN SACHS GROUP, INC. | 6.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Jasper Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Jasper Therapeutics, Inc. and the records around it.
Jasper Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Aug 2026
- Acquisition Jul 2026
- Who owns it
Companies that share a holder
- Kingdon Capital Management, L.L.C. also filed stake reports on 2 other companies: enVVeno Medical Corporation (May 2026), SCYNEXIS INC (Feb 2026)
- Velan Capital Master Fund LP also filed stake reports on 2 other companies: Edesa Biotech, Inc. (Aug 2026), InspireMD, Inc. (May 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026)
Watch Jasper Therapeutics, Inc.
Get an email when Jasper Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jasper Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Jasper Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jasper Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-28 | In | Principal Financial Officer | 8-K, 2026-09-28 | ||
| 2026-07-17 | In | Director | 8-K, 2026-07-17 | ||
| 2026-05-21 | Out | 8-K, 2026-05-21 |
Who leads Jasper Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Financial Officer: Jeet Mahal, appointed (filed 2026-09-28).
- Director: Patrick Crutcher, appointed (filed 2026-07-17).
New leaders reset buying decisions — get the Full Report on Jasper Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Financial Officer at Jasper Therapeutics, Inc., with the record behind each one.
Find candidates like Principal Financial Officer at Jasper Therapeutics, Inc.Every change, in the filing's words
Appointed: Jeet Mahal, Principal Financial Officer
On September 28, 2026, the board of directors of the Company appointed Jeet Mahal, the Company's President and Chief Executive Officer, as interim Principal Financial Officer, Rick Ruiz, the Company's Vice President, Finance, as interim Principal Accounting Officer and Matthew Ros, the Company's Chief Operating Officer, as the interim Corporate Secretary, each effective as of Mr. Cross' resignation.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the "Company") in order to pursue other professional endeavors.
- Mr. Mahal's biographical and compensation information may be found in the Company's Amendment No. 1 to Form 10-K, filed with the Securities and Exchange Commission on April 30, 2026.
- Mr. Ruiz, age 62, joined the Company in 2024 as Vice President, Finance.
- Mr. Ruiz is an accomplished finance executive with over 25 years of experience encompassing accounting, financing, FP&A and SEC reporting.
- Mr. Ruiz previously served as Vice President, Finance at Atreca.
- Prior to Atreca he was a consultant at RoseRyan, a leading finance and accounting consulting firm, as well as Corporate Controller at Audible Magic Corp. Mr. Ruiz began his career at KPMG and received a Bachelor of Science in Business Administration from Biola University.
- He is a certified public accountant, currently inactive, in the state of California.
Appointed: Patrick Crutcher, Director
Appointment of Director In accordance with the Merger Agreement, on July 16, 2026, the Board appointed Patrick Crutcher, age 41, to the Board as a Class I director, effective as of immediately after the Effective Time.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Resignation of Directors In accordance with the Merger Agreement, on July 16, 2026, Vishal Kapoor and Scott Brun, M.D., notified the Board of their resignations, each effective immediately after the Effective Time.
- Neither Mr. Kapoor's nor Dr. Brun's resignation is a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In connection with the resignations of Mr. Kapoor and Mr. Brun from the Board, the Board reduced the authorized number of members of the Board from eight to six, effective immediately after the Effective Time.
- Mr. Crutcher has over 15 years' experience establishing and building private and public biotechnology companies, with a focus on business development, precision therapeutics for rare diseases and biologics in drug development.
- Mr. Crutcher is currently the Founder & Chairman of AstralBio, Inc., MPN Therapeutics, Inc., ImmuneStudio, Inc. and is managing member of Chyma Bioventures LLC.
- He also co-founded Helicore Biopharma, Inc., an obesity company backed by Orbimed and Versant.
- Mr. Crutcher served as Co-Founder, CEO and director of Mach5 Therapeutics from April 2024 through the company's acquisition by Kira in March 2026.
Departing: Christian Nolet
On May 15, 2026 (the "Notice Date"), Christian Nolet informed the Board of Directors (the "Board") of Jasper Therapeutics, Inc. (the "Company") that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.
- Mr. Nolet's resignation is not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Board has appointed Svetlana Lucas, Ph.D. as a member of the Audit Committee of the Board.
Tools for this story
Each opens in a new tab, filled in for Jasper Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.